Immutep (IMM) Fundamentals 2026 — Revenue Analysis | SniperIQ
Immutep (IMM) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$74M, trading at A$0.05 on the ASX. This SniperIQ fundamentals page covers Immutep's valuation, profitability (net margin -1404.1%), revenue (A$5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Immutep's market cap?
Immutep (IMM) has a market capitalization of approximately A$74M, trading at A$0.05 on the ASX. Market cap moves with the live share price.
What is Immutep's P/E ratio?
Immutep's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Immutep?
Immutep runs a net profit margin of -1404.1%, a gross margin of -522.6%, and an operating margin of -2052.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Immutep generate?
Immutep reported revenue of A$5M for fiscal year 2025, with net income of -A$61M and earnings per share (EPS) of -0.0422. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Immutep pay a dividend?
Immutep does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Immutep financially healthy?
Immutep carries a debt-to-equity ratio of 0.02x and a current ratio of 2.97x, with a market beta of 2.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Immutep a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Immutep (IMM) the key facts are: market cap A$74M, revenue A$5M, 52-week range 0.028-0.47. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Immutep's full fundamentals live
Get Immutep's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.